Head of Investor Relations
Mirum Pharmaceuticals, Inc. (MIRM)Equibles does not estimate personal net worth.
Get an email with a short summary when Mirum Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get MIRM alertsAndrew McKibben is recorded as Head of Investor Relations at Mirum Pharmaceuticals, Inc. (MIRM). Andrew McKibben has spoken on 13 earnings calls and 4 other investor events across 1 company, most recently for Mirum Pharmaceuticals, Inc. on November 11, 2026. Mirum Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Mirum Pharmaceuticals, Inc. includes Christopher Peetz (CEO), Michael Grey (CEO), Eric Bjerkholt (CFO) and 6 others.
“We're planning to file in the first half of next year. We received feedback in July from the FDA at our pre-NDA meeting. They recommended a phase three but noted that we could file at our discretion.”
“But, you know, effectively, I mean, there's no material update to provide. I mean, our conversations are progressing. You know, everything's on plan for a submission in the first half of next year.”
“I'd like to welcome you to Miriam Pharmaceutical's third quarter 2026 conference call. I'm joined today by our Chief Executive Officer, Chris Peets, our President and Chief Operating Officer, Peter Radovich, our Chief Medical Officer, Rob Myers, and our Chief Financial Officer, Eric Bierkolt.”
“I'd like to welcome you to Miriam Pharmaceuticals' second quarter 2026 conference call. I'm joined today by our Chief Executive Officer, Chris Peets, our President and Chief Operating Officer, Peter Radovich, and Eric Bierkolt, our Chief Financial Officer.”
“And we kind of talk about with Marley being over a billion in peak potential and really see allergy old PFIC and then this kind of expand basket indication as roughly being equal components of that.”
Biotechnology · Healthcare
Head of Investor Relations
